surpass cvot tirzepatide Post hoc analysis of SURPASS-CVOT trial: was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and ๐ก New insight in diabetes
Pay in 4 interest-free payments of $5.84 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 13 - Aug 18
























